Literature DB >> 33074528

Metabolism and immunity in breast cancer.

Deyu Zhang1, Xiaojie Xu2, Qinong Ye3.   

Abstract

Breast cancer is one of the most common malignancies that seriously threaten women's health. In the process of the malignant transformation of breast cancer, metabolic reprogramming and immune evasion represent the two main fascinating characteristics of cancer and facilitate cancer cell proliferation. Breast cancer cells generate energy through increased glucose metabolism. Lipid metabolism contributes to biological signal pathways and forms cell membranes except energy generation. Amino acids act as basic protein units and metabolic regulators in supporting cell growth. For tumor-associated immunity, poor immunogenicity and heightened immunosuppression cause breast cancer cells to evade the host's immune system. For the past few years, the complex mechanisms of metabolic reprogramming and immune evasion are deeply investigated, and the genes involved in these processes are used as clinical therapeutic targets for breast cancer. Here, we review the recent findings related to abnormal metabolism and immune characteristics, regulatory mechanisms, their links, and relevant therapeutic strategies.

Entities:  

Keywords:  breast cancer; cancer stem cells; immunity; metabolism

Year:  2020        PMID: 33074528     DOI: 10.1007/s11684-020-0793-6

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  315 in total

Review 1.  Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations.

Authors:  Rokaya El Ansari; Alan McIntyre; Madeleine L Craze; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Histopathology       Date:  2017-10-17       Impact factor: 5.087

2.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.

Authors:  Steven A Roberts; Michael S Lawrence; Leszek J Klimczak; Sara A Grimm; David Fargo; Petar Stojanov; Adam Kiezun; Gregory V Kryukov; Scott L Carter; Gordon Saksena; Shawn Harris; Ruchir R Shah; Michael A Resnick; Gad Getz; Dmitry A Gordenin
Journal:  Nat Genet       Date:  2013-07-14       Impact factor: 38.330

Review 3.  Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses.

Authors:  Rinke Stienstra; Romana T Netea-Maier; Niels P Riksen; Leo A B Joosten; Mihai G Netea
Journal:  Cell Metab       Date:  2017-07-05       Impact factor: 27.287

Review 4.  Biological subtypes of breast cancer: Prognostic and therapeutic implications.

Authors:  Ozlem Yersal; Sabri Barutca
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 5.  Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.

Authors:  Rigel J Kishton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Cell Metab       Date:  2017-07-05       Impact factor: 27.287

6.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

7.  Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.

Authors:  Karolina Holm; Cecilia Hegardt; Johan Staaf; Johan Vallon-Christersson; Göran Jönsson; Håkan Olsson; Ake Borg; Markus Ringnér
Journal:  Breast Cancer Res       Date:  2010-06-18       Impact factor: 6.466

8.  Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Yee Chung Cheng; Gabriela Rondón; Paolo Anderlini; Issa F Khouri; Richard E Champlin; Naoto T Ueno
Journal:  J Cancer       Date:  2013-09-27       Impact factor: 4.207

Review 9.  Metabolic Footprints and Molecular Subtypes in Breast Cancer.

Authors:  Vera Cappelletti; Egidio Iorio; Patrizia Miodini; Marco Silvestri; Matteo Dugo; Maria Grazia Daidone
Journal:  Dis Markers       Date:  2017-12-24       Impact factor: 3.434

10.  Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Authors:  Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

View more
  6 in total

1.  Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer.

Authors:  Yin-Wei Dai; Zhi-Kai Wen; Zhi-Xuan Wu; Hao-Dong Wu; Lin-Xi Lv; Cong-Zhi Yan; Cong-Hui Liu; Zi-Qiong Wang; Chen Zheng
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

Review 2.  Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors.

Authors:  Xianhu Zeng; Zhipeng Li; Chunrong Zhu; Lisa Xu; Yong Sun; Shangcong Han
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 3.  Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer.

Authors:  Chiara Francavilla; Ciara S O'Brien
Journal:  Open Biol       Date:  2022-02-23       Impact factor: 6.411

4.  A novel pyroptosis-related indicator of immune infiltration features and prognosis in breast cancer.

Authors:  Cheng Wang; Liyong Zhang; Lin Ren; Guozhi Zhang; Andi Wan; Siyi Xiong; Hao Tian; Zaihui Peng; Tingting Zhao; Pingping Gao; Na Sun; Yi Zhang; Xiaowei Qi
Journal:  Front Oncol       Date:  2022-09-07       Impact factor: 5.738

5.  Role of copper ionophore-induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis.

Authors:  Shunyao Xia; Haixing Jia; Zhipeng Qian; Youcheng Xiu
Journal:  Front Genet       Date:  2022-10-03       Impact factor: 4.772

Review 6.  Phosphatases of regenerating liver are key regulators of metabolism in cancer cells - role of Serine/Glycine metabolism.

Authors:  Pegah Abdollahi; Esten N Vandsemb; Magne Børset
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2022-01-01       Impact factor: 4.294

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.